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Abstract Although common in women, mixed urinary
incontinence (MUI) is under-reported and under-treated.
It is linked to concomitant disturbances, which may be
due to childbirth, ageing, or other medical conditions, in
the complex bladder-urethra coordinated system of urine
storage and emptying. Primary care physicians can eval-
uate MUI through history and simple clinical assessment
or they can avail of more complex device and tools,
such as urodynamic assessment. There is a wide range
of therapeutic options. The recent proliferation of new
drug treatments and surgical devices for urinary incon-
tinence offers innovative strategies for therapy but prod-
ucts risk being introduced without long-term safety and
efficacy assessment. Direct-to-consumer advertising has
increased public awareness of MUI.
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Introduction
Mixed incontinence, usually considered as a combination of
stress incontinence and urgency incontinence, is highly
prevalent in everyday clinical practice. Several physicians
fail to take account of wide variation in the relative impor-
tance of the stress and urgency components experienced by
patients. The lack of clarity awareness regarding the real
clinical picture makes diagnosis and management extremely
difficult. The purpose of this paper is to improve bedside
awareness regarding women with mixed urinary inconti-
nence providing a snapshot over definitions, diagnosis and
treatment by pointing out the traditional and recent advances
in treatment options.
Definition
The International Continence Society’s (ICS) standardized
nomenclature of MUI is: complaint of involuntary leakage
associated with urgency and also with exertion, effort,
sneezing or coughing [1]. When urodynamic assessment is
performed, MUI is represented by stress incontinence and
detrusor overactivity (DO) with or without incontinence.
Unfortunately, in daily clinical practice symptomatic and
urodynamic definitions fail to take wide variations into
account. Generally speaking patients fall into two main
categories: those with urodynamic stress incontinence and
DO with incontinence (OAB wet) and those with urody-
namic stress incontinence and DO without incontinence
(OAB dry). We should also bear in mind the following
definitions: clinical MUI, based only on clinical evaluation
and urodynamic MUI. Finally, a proposal was made to use
the terms “mixed incontinence”, when incontinence was
objectively shown and “mixed symptoms of incontinence”
when it was subjectively reported by patients.
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The definitions of MUI encompass different aspects of the
same kind of incontinence. The Urinary Incontinence Treat-
ment Network upheld the view that MUI definitions did
not adequately categorize clinically relevant UI subgroups
[2•]. Indeed, no definition provides answers to the ques-
tions as to what the predominant type is or what the most
bothersome type is in the patient’s perspective. Semantic
definitions of urge predominant MUI or stress predominant
MUI were introduced to facilitate practical use and orient
treatment.
Epidemiology
A large, population-based survey of USAwomen aged 30–90
years, revealed about 45% prevalence of urinary incontinence
of any kind/any type and half the incontinent women had
MUI symptoms [3]. The NOBLE survey estimated that 5.2
million adults aged >18 years had mixed incontinence [4]. In
a Norwegian questionnaire-based estimate, the prevalence of
urinary incontinence was 25%, with 36% MUI [5]. Confirm-
ing American findings [3] Minassian et al., observed the
overall prevalence of MUI in women was 14.5%, with 57%
reporting severe MUI incontinence compared with 36% and
37% of women with stress (SUI)- or urge (UUI)-only urinary
incontinence [6]. The prevalence rates of urinary inconti-
nence subtype varied with responders’ age, ethnicity, how
the question was asked, and how the subtype was defined [4,
7, 8]. Patients with MUI and UUI scored worse than those
with SUI but no significant differences were found in HRQoL
scores in patients with MUI and UUI, meaning that urgency
in mixed incontinence has a greater impact on quality of life
than stress [9].
Pathophysiology
Normal continence in women is a complex coordination of
bladder, urethra and pelvic muscles as well as surrounding
connective tissues. MUI is caused by disturbances in storage
and emptying. Urethral sphincter dysfunction and bladder
dysfunction may coexist in individuals, and insisting that
patients fit into one specific category could compromise clin-
ical care. Four pathophysiological theories to account for SUI
dominate the literature:
i) Alterations in the urethrovesical axis: incontinence
depends on a sudden, abnormal displacement of the ure-
thra and the urethro-vesical junction immediately behind
the pubic symphysis. This theory is supported by evidence
that anatomy, topography and mutual spatial relationships
are essential for district function. However, since the
urethral axis at rest, during bearing down and in its total
excursion, was not found to be significantly different in
continent and incontinent women, the urethral axis and its
sphincter function could not be correlated [10].
ii) Intrinsic sphincter deficiency: In 1977 McGuire sug-
gested that SUI depended on a sphincter mechanism
deficiency. Loss of intrinsic sphincter integrity together
with age-dependent rabdosphincter apoptosis could play
major roles in the development of female incontinence.
Unfortunately, evidence does not fully support this the-
ory as 51% of continent climateric women had bladder
neck incompetence and 21% of continent nulliparous
women had an open bladder [11].
iii) Hammock theory: In 1994 DeLancey reported that the
urethra lay on a supportive layer of endopelvic fascia
and anterior vaginal wall and was stabilized by its lateral
attachments to the arcus tendineus fascia and levator ani.
Urethral closure depends on urethral compression
against the rigid support of pubocervical fascia and
anterior vaginal wall. MRI findings supported the theory
as they confirmed thinning of the urethra, a high degree
of puborectalis asymmetry and distortion of periurethral,
pubourethral and paraurethral ligaments in incontinent
women [12, 13]. Post-mortem and other anatomical
studies, however, found three-fold variations in levator
ani muscle thickness, endopelvic fascia and urethra
thickness were also present in continent women [14].
iv) Integral theory: More recently Petros and Ulmsten
argued that “the laxity of the anterior vagina wall leads
to activation of stretch receptors in the bladder neck and
proximal urethra, resulting in dissipation of urethral
closure pressure and inappropriate activation of mictu-
rition reflex”. This last theory has been advocated to
explain both SUI and MUI.
The pathophysiology of MUI needs to involve factors such
as striated muscle atrophy, oestrogen status, histomorpholog-
ical abnormalities and ultrastructural changes, all of which are
under study. Although beyond the scope of the present article,
it is important to mention that women with MUI may have
decreased vaginal collagen content, increased vaginal mRNA
matrix metalloproteinases and a greater collagen breakdown
[15].
The pathophysiology of urgency/OAB and UUI remains
poorly understood. UUI and OAB may be due to afferent
dysfunction, CNS incapacity to handle information and
evoke adequate answers as well as independent activity of
the periphery.
In conclusion, one theory or one risk factor is insuffi-
cient to explain the complexity of MUI. Consequently, the
“trampoline theory” attempts to encompass all the factors
that may play a role in MUI [16]. Although malfunction
of one element in the continence mechanism rarely results
in MUI, malfunction of several elements and inability to
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compensate for loss of function, means the” trampoline”
will malfunction.
Therapy
MUI treatment consists of conservative management, phar-
macotherapy and surgery.
Conservative Management
Conservative management comprises any therapy that does
not involve pharmacological or surgical intervention. It can be
initiated after simple assessment in many patients and should
be considered the mainstay of primary care treatment of
women with MUI. It includes lifestyle interventions, bladder
retraining, anti-incontinence devices, biofeedback, comple-
mentary therapies and pelvic floor muscle exercises
(PFME). The goals of behavioral training are to correct void-
ing patterns, improve the ability to suppress urge and increase
bladder capacity and continence. The benefits of weight loss
are supported by level 2 evidence in morbidly obese patients
and level 1 evidence in moderately obese patients [17]. No
data have been reported on the impact of smoking cessation
on incontinence. Evidence about caffeine, alcohol or fluid
intake is conflicting. As obesity is known to be a modifiable
risk factor for SUI, Subak et al. investigated whether weight
loss was effective treatment of MUI [18•]. In a randomized
controlled trial, 338 overweight and obese women, most of
whom are suffering from MUI with urinary incontinence,
were randomized to an intensive weight-loss program and
behavior modification or to a structured education program.
After 6 months women in the weight-loss program lost sig-
nificantly more weight and had significantly fewer inconti-
nence episodes weekly than those in the education group.
Grade A evidence recommendation supports use of
PFME in women with MUI [17] as the overall cure/im-
provement rates ranged from 56 to 70%.
Pharmacotherapy
Since MUI has been regarded as two coexisting disorders
(SUI/UI), first-line drugs help both conditions, with treat-
ment focusing on the pathophysiology of predominant
symptoms. The main drug strategies consist of hormone
replacement, drugs targeting SUI, drug targeting UUI and
drugs with a balanced activity over SUI and UUI.
In the treatment of SUI and MUI data are contradictory on
the efficacy of topical and systemic oestrogens. Even though
the Cochrane review (15 RCT studies) showed that inconti-
nence improved with hormone replacement therapy (HRT)
[19], oral or transdermal oestrogen may increase the risk of
incontinence [20]. The International Consultation on
Incontinence gave oestrogen a grade D recommendation and
advised against using it as treatment for incontinence.
Some studies of antimuscarinic drugs and SNRIs (se-
rotonin/norepinephrine reuptake inhibitors) suggested that
each substance had a positive effect on MUI [21]. Al-
though no robust data support the effectiveness of Imip-
ramine in MUI, it was recommended because of its dual
action of anticholinergic and noradrenergic or serotoner-
gic reuptake inhibition. It has low morbidity and variable
success but may be useful in young and elderly women
who are not candidates for surgery. Imipramine received
a grade D recommendation for the treatment of SUI.
Duloxetine was the first drug the EMA specifically ap-
proved for the treatment of SUI. In a preliminary study in
women with MUI, median MUI episodes were reduced by
62% at 40 mg/daily and by 63% at 80 mg/daily. In a
randomized, placebo-controlled, double-blind clinical trial
Bent and colleagues randomized 588 women with MUI to
80 mg daily duloxetine or placebo [22]. Overall, episodes of
frequency, stress and urge incontinence were significantly
fewer with duloxetine. Similar findings were reported in
elderly women with stress predominant MUI [23].
Evidence supports the use of antimuscarinic agents (oxy-
butynin, tolterodine, solifenacin and fesoterodine) in MUI as
well as in OAB [24]. Sincemost studies considered subgroups
of patients with MUI within studies on OAB, few investiga-
tions specifically targeted their effects on MUI. Karram and
Bhatia reported that 32% of 52 patients with SUI and UUI
were cured and 28% improved [25]. Dmochowsky et al. found
that 3.9 mg transdermal oxybutynin significantly improved
symptoms in patients with MUI [26]. Goepel found that
symptoms regressed in 60% of 410 patients with MUI [27].
Kreder et al. compared the efficacy of tolterodine twice daily
in 239 patients with urge-predominant MUI and 755 patients
with UUI alone, reporting no significant between-group dif-
ferences, with dry rates of 39% and 44%, respectively [28]. In
the Mixed Incontinence Effectiveness Research: Investigating
Tolterodine (MERIT) study, 854 women with urge predomi-
nant MUI were randomized to 4 mg extended release (ER)
tolterodine or placebo for 8 weeks [29]. There were 12.3
weekly incontinence episodes fewer in patients undergoing
active treatment and eight episodes fewer in those taking
placebo. In a prospective, randomized study with solifenacine
(5–10 mg), 1041/2696 women (39%) with urgency-
predominant MUI achieved median reductions in inconti-
nence episodes of 82% (5 mg) and 94% (10 mg) vs 64%
placebo. Urgency episodes were reduced by a median of 73%
(5 mg) and 69% (10 mg) vs. 42% placebo [30].
Surgery
Since surgery is used mainly to treat SUI, primary physicians,
urologists and gynecologists should include the option of
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surgery during treatment counseling for women with predom-
inant SUI. Once surgery is decided, a consultation with a
dedicated surgeon is mandatory so as to offer the most choices
to the patient. The best approach has not yet been defined.
Surgical treatment of MUI includes retropubic colposuspen-
sion (Burch procedure), a pubovaginal sling, and recently, the
new mid-urethral slings (TVT/TOT) which are largely mod-
ifications of the pubovaginal sling. Although some recent
papers described surgical treatment of MUI, few reports com-
pared different types of anti-incontinence surgery head-to-
head. A prospective study randomized 75 women with MUI
to anticholinergic agents or surgery (Burch colpususpension
vs PVS); 20 patients with pure SUI undergoing surgery served
as controls. After 6 months, no significant differences
emerged: 87% of women with MUI who underwent Burch
were dry compared with 83% after PVS; persistent urge
incontinence was similar in the two groups [31].
Several retrospective studies assessed the efficacy of di-
verse surgical procedures in treating MUI. Gamble et al.
recruited 305 women who underwent transobturator, retropu-
bic, or bladder neck sling for MUI and found that transobtu-
rator slings had the lowest rate of persistent DO [32].
Rezapour and Ulmsten reported a subjective 85% cure rate
in women with MUI after tension-free vaginal tape (TVT)
[33]. Although cure rates of MUI after TVT surgery were
substantial, they were significantly lower than in women with
pure SUI [34]. When comparing first- and second-generation
mid-urethral slings, Paick et al. reported on 144 women with
MUI who underwent TVT, SPARC, or TOTand found similar
cure rates in all three groups for SUI (96%, 90%, and 94%,
respectively) and UUI (82%, 86%, and 82%, respectively)
[35]. They also reported that preoperative low maximum
urethral closure pressure and DO were both associated with
increased likelihood of treatment failure of UUI. In a prospec-
tive, multi-centre, randomized study comparing TVT and
TOT procedures for MUI Kocjancic et al. analyzed 116 con-
secutive women with stress or mixed UI randomized to TVT
(61) or to TOT (55). They showed that with both procedures
the most frequent late complication was de novo urgency.
Post-operative storage symptoms were not significantly dif-
ferent in the TVT group but were significantly lower in the
TOT group. The storage symptom cure rate was 31% after
TVT and 55% after TOT [36].
Jain et al. recently reviewed current literature on the impact
of mid-urethral slings on MUI symptoms [37••], locating six
RCTs and seven prospective non-randomized studies of aver-
age to good quality that included women with symptomatic
and/or urodynamic MUI. The overall subjective cure rate in
these seven studies was 56.4% at 35 months of follow-up. The
overall cure of urinary urgency and the UUI component
ranged from 30 to 85% with follow-ups ranging from a few
months to 5 years; most studies suggested the cure rate waned
over time. In a meta-analysis of five RCTs which included
women withMUI symptoms, the odds of an overall subjective
cure with TVT vs. TOTwere similar at 6–33 months follow-
up; this finding remained true in a subgroup analysis on
women with MUI who did not have urodynamic DO.
The remaining question is whether characteristics of a
patient’s urge or UUI can predict surgical failure or success.
To provide better information for surgical outcomes attempts
were made to define MUI using questionnaire scores that
looked separately at Medical, Epidemiological and Social
Aspects of Aging (MESA) subscale scores as well as amount
of bother according to the Urogenital Distress Inventory
(UDI). They were, however, found to be inadequate. Paick
et al. reported that the presence of DO was a risk factor for
treatment failure for UUI [35]. Schrepferman et al. analyzed a
series of 69 patients who underwent PVS for urodynamic SUI
with preoperative urge symptoms, 41 with motor urge (DO;
further subdivided into 23 patients with low-pressure and 18
with high-pressure urge) and 28 with sensory urge. Urge
symptomswere completely resolved in 91.3% of patients with
low pressure motor urge compared with 27.8% with high-
pressure and 39.3% with sensory urge [38].
Similarly, one may also wonder whether outcomes in
women undergoing anti-incontinence surgery with an urge
component are worse than outcomes in women with pure
SUI. Holmgren et al. evaluated 760 questionnaire respond-
ents who had undergone TVT (112 for MUI, 580 for SUI).
Long-term cure rates according to answers to a question
regarding incontinence status after surgery as “cured” or
“almost cured” were stable at about 85% from 2 to 8 years
in the pure SUI group. Cure rates in the MUI group
remained around 60% until 4 years, after which they steadi-
ly declined to about 30% at 6–8 years [39]. Although the
predictive factors of outcome after surgery for MUI remain
controversial, multivariable analysis of large series of
patients in multi-centre studies could answer our questions
in the near future.
Conclusion
The challenge in identifying an ideal treatment modality
for MUI lies in the difficulty in defining it and in lack of
consistent coordination between subjective symptoms and
urodynamic findings. Furthermore, an effective single
treatment may well not even exist. Successful treatment
of UUI may make SUI symptoms more prominent and
treatment of SUI may be associated with de-novo or
persistent UUI symptoms. Although it is clearly not
feasible to restrict treatment exclusively to high-volume
centres, treatment trends are shifting so that more patients
are treated by high-volume providers. This will improve
MUI control and decrease women’s dissatisfaction, im-
proving their quality of life.
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